anti inflammatory drugs

Canakinumab      

pathologytreatmentpatient Demonstrated benefit and harm k      
percutaneous coronary interventionpexelizumabnot classified

versus placebo or control

No demonstrated result for efficacy

1 trialmeta-analysis